Katy Marshall

DocwireNews

The current standard nonoperative treatment for locally advanced esophageal cancer is concurrent chemoradiotherapy.
A phase 2 trial conducted by Kuaile Zhao, MD, and colleagues sought to determine if a treatment regimen of PD-1 inhibitors and chemoradiotherapy has the potential to benefit esophageal tumor vascular normalization, alleviate hypoxia, enhance radiosensitivity, and improve local control.
The study was <a href="https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00050-6/fulltext#%20" target="_blank" rel="noopener">published in eClinicalMedicine</a>. 
Dr. Zhao and colleagues observed that local recurrence in patients with esophageal cancer is the primary reason for more than half of treatment failures and that the sensitivity of radiotherapy is lacking.
The multicenter, single-arm trial included 75 patients with locally advanced esophageal cancer who received 2 cycles of sintilimab, paclitaxel, and carboplatin once every 21 days. While in the concurrent phase, patients received 5 cycles of carboplatin and paclitaxel once per week with radiotherapy of 50.4 Gy delivered in 28 fractions.
Researchers evaluated hypoxia and vessel normalization using immunofluorescence and perfusion computed tomography (CT) prior to and following the induction phase. The study’s primary end point was the 2-year local control rate.
Of the 75 patients who received treatment between October 2019 and April 2021, the median follow-up of surviving patients was 33.6 months. The 2-year local control rate was 81.7% (95% CI, 72.7-90.7), which was a significant increase from previous studies investigating concurrent chemoradiation (71.3%).
Investigators noted that vascular normalization and hypoxia alleviation were both found in biopsy specimens and perfusion CT.
Dr. Zhao and colleagues observed that induction immunotherapy plus concurrent chemoradiotherapy may be a viable option for improving radiosensitivity as a nonsurgical treatment option for patients with locally advanced esophageal cancer. They also remarked that the therapy combination increased the local control rate by improving vascular normalization and alleviating hypoxia.
“Our findings suggest that induction immunotherapy followed by concurrent chemoradiotherapy could be a potential option in future treatment,” researchers stated.

Rob Dillard

Analyzing Rural and Urban Patterns of Monitoring of Implanted Cardiac Devices

AHA 2024

Left Atrial Appendage Closure Devices Effective at Preventing Stroke in Very Elderly Patients

Emily Menendez

Non-Invasive NETseq Classifier Determines NET Diagnosis With High Accuracy, Sensitivity

GEP-NETs

Latest News

Does Induction Immunotherapy Benefit Patients With Advanced Esophageal Cancer?

Gastroesophageal Cancer

Patients received 2 cycles of sintilimab, paclitaxel, and carboplatin once every 21 days.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe